3BNC117 vs Zinlirvimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
3BNC117
Developed by Frontier Biotechnologies and partners
NCT03041012 · Phase 2 · completed
This open-label, randomized Phase 1b/2a trial assigned 55 people newly diagnosed with HIV-1 to four groups: standard antiretroviral therapy alone, or with the antibody 3BNC117, romidepsin, or both. The first primary measure, the early fall in blood virus levels, was faster with 3BNC117 plus romidepsin than with therapy alone between days 10 and 24 (P=0.048). The second primary measure, the number of immune cells that carry intact virus after one year, fell in all groups, with no significant difference between groups. Because one primary measure was met and one was missed, the result is mixed. The figures come from the peer-reviewed report of the trial in Nature Medicine.
Reported efficacy
Plasma HIV RNA kinetics (3 months); Quantification of the size of the proviral HIV reservoir (1 year); Time to viral rebound during ATI (12 weeks): Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed. (mixed)
Result source: NCT03041012
Zinlirvimab
Developed by Gilead Sciences under a licence from The Rockefeller University
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07054931 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | 3BNC117 | Zinlirvimab |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Trial running · NCT07683000 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Trial running · NCT07683000 |
| CD4 count, change (week 48) | —Not reported | —Trial running · NCT07683000 |
HIV-1 RNA below 50 copies/mL (week 48)
- 3BNC117
- —Not reported
- Zinlirvimab
- —Trial running · NCT07683000
HIV-1 RNA 50 copies/mL or more (week 48)
- 3BNC117
- —Not reported
- Zinlirvimab
- —Trial running · NCT07683000
CD4 count, change (week 48)
- 3BNC117
- —Not reported
- Zinlirvimab
- —Trial running · NCT07683000
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zinlirvimab: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. 3BNC117: 3 of 4 rows · Zinlirvimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | 3BNC117 |
|---|---|
| Dropout rate | 11.8%a NCT02588586 · Phase 2 · registry result, not featured evidence · combination show 2 more results0%Group A: 3BNC117 IV + ART Interrup NCT02446847 · Phase 2 · registry result, not featured evidence · combination 25%Group B: 3BNC117 IV + ART Interrup NCT02446847 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT02588586 · Phase 2 · registry result, not featured evidence · combination show 2 more results—Group A: 3BNC117 IV + ART Interrup NCT02446847 · Phase 2 · registry result, not featured evidence · combination —Group B: 3BNC117 IV + ART Interrup NCT02446847 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 5.9%a NCT02588586 · Phase 2 · registry result, not featured evidence · combination show 2 more results0%Group A: 3BNC117 IV + ART Interrup NCT02446847 · Phase 2 · registry result, not featured evidence · combination 12.5%Group B: 3BNC117 IV + ART Interrup NCT02446847 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a malaise 23.5% nausea 23.5% diarrhea 17.6% NCT02588586 · Phase 2 · registry result, not featured evidence · combination show 2 more resultsheadache 75% upper respiratory tract infection 62.5% paresthesia upper extremity 37.5% NCT02446847 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 75% headache 25% anemia 12.5% NCT02446847 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
3BNC117
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 3BNC117's landscape · Zinlirvimab's landscape